跳至主要内容
临床试验/NCT01472497
NCT01472497已完成4 期

Effects of Pioglitazone and Glimepiride in Hypertensive Patients - Relationship With AGE, Inflammatory Cytokines and Cardiac Markers -

Tottori University Hospital1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2007年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
16
试验地点
1
主要终点
advanced glycation end-product (AGE)

研究概览

简要总结

Insulin resistance is often complicated with hypertension. AGE and inflammation play important roles in insulin resistance. Some studies reported that pioglitazone, insulin sensitizer, is effective for patients with insulin resistance, however, the mechanisms are still unclear. The aim of this study to evaluate the effect of pioglitazone compared with glimepiride on AGE, inflammatory cytokines and cardiac markers (BNP and echo) in hypertensive patients during oral glucose tolerance test.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hypertension with insulin resistance

排除标准

  • Chronic systolic heart failure, ACS

研究组 & 干预措施

glymepiride

Experimental

干预措施: Pioglitazone (Drug)

结局指标

主要结局

advanced glycation end-product (AGE)

时间窗: 24 weeks

inflammatory cytokines (TNF-alfa, IL-6 and MCP-1)

时间窗: 24 weeks

cardiac function (echo and BNP)

时间窗: 24 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kazuhide Ogino

Associate Professor

Tottori University Hospital

研究点 (1)

Loading locations...

相似试验